The authors found that CXCR3 ligands (CXCL9, 10, and 11) were all expressed at higher rates by central tumor tissue than non-tumor tissue, while there was no difference in CXCR3 and CCR5 ligand expression across tissues. This evidence concerns the gene CXCL9 and neoplasm.